Scrip's Pharma Influencers Of 2016
The Scrip editorial team have put their heads together to make a list of the people that we believe have shaped the biopharma industry in 2016 – in terms of reputation, innovation or commercialization. In the way of Time magazine's 'Person of the Year', inclusion on the list is not necessarily an accolade…
You may also be interested in...
Since becoming CEO of Shire in April 2013, Flemming Ornskov has overseen around $50bn in M&A deals. He steered the company through the ultimately abortive takeover by AbbVie and walked away with a break fee of $1.6bn, going on to consummate instead Shire’s $32bn acquisition of Baxalta earlier this year. He spoke to Scrip about his vision and values.
To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.